BioSpace News Archive

AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, including rare diseases with high unmet medical needs, announces the appointment of the experienced pharmaceutical executive Michael Soldan, PhD, as its Chief Executive Officer.

Targovax ASA announces that it has completed patient enrollment in the phase I trial with ONCOS-102 in combination with Keytruda in patients with advanced anti-PD1 checkpoint inhibitor refractory melanoma.

Vifor Pharma announced that Fitch Ratings has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook.

The designation is based on results from a Phase II trial, which suggested Esbriet slowed disease progression in patients with uILD at 24 weeks

GenSight Biologics announced that the bilateral visual recovery observed with GS010 in the REVERSE and RESCUE Phase III trials will be presented and discussed at the 46th Annual Meeting of the North American Neuro-Ophthalmology Society - Amelia Island, Florida - March 7-12, 2020.

Multiple ascending dose and food effect study will be a follow-up to a previously conducted single ascending dose clinical trial of LYT-100

BioArctic AB announced that the company’s partner Eisai will include Swedish clinics in the confirmatory Phase 3 study of the drug candidate BAN2401.

Richard Twomey, President and CEO of Mölnlycke, will after six years leave the organisation.

Oncolytic Virus Design and Preclinical Data to be Presented at ESMO TAT, IO Summit Europe, Keystone Symposium and AACR 2020

Mobile Diagnostic Labs will soon be heading to a community near you to test for the novel coronavirus Covid-19.